Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated